• LAST PRICE
    1.6100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.5900/ 1
  • Ask / Lots
    1.6100/ 9
  • Open / Previous Close
    1.6400 / 1.6100
  • Day Range
    Low 1.6100
    High 1.6400
  • 52 Week Range
    Low 1.2500
    High 7.9010
  • Volume
    15,554
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.61
TimeVolumeCLRB
09:32 ET1201.64
09:33 ET30001.64
09:37 ET30001.6399
09:39 ET60001.61
09:42 ET22081.6101
10:33 ET1001.61
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCLRB
Cellectar Biosciences Inc
15.1M
-0.4x
---
United StatesONPH
Oncology Pharma Inc
14.8M
0.0x
---
United StatesPCSA
Processa Pharmaceuticals Inc
16.0M
-1.0x
---
United StatesPYPD
PolyPid Ltd
16.1M
-0.3x
---
United StatesBWV
Blue Water Vaccines Inc
19.3M
-1.1x
---
United StatesLEXX
Lexaria Bioscience Corp
17.9M
-2.6x
---
As of 2023-02-03

Company Information

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.

Contact Information

Headquarters
100 Campus DriveFLORHAM PARK, NJ, United States 07932
Phone
608-441-8120
Fax
608-441-8121

Executives

Independent Chairman of the Board
Douglas Swirsky
President, Chief Executive Officer, Director
James Caruso
Chief Financial Officer, Vice President, Secretary
Chad Kolean
Chief Operating Officer
Jarrod Longcor
Vice President - Marketing and Strategic Alliances
Matthew Hagan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$15.1M
Revenue (TTM)
$0.00
Shares Outstanding
9.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.21
EPS
$-4.47
Book Value
$5.41
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.